Novo Nordisk or Eli Lilly? The Billion-Dollar GLP-1 Battle Is Heating Up
The global pharmaceutical industry is witnessing one of the biggest healthcare competitions in history. Two industry giants—Novo Nordisk and Eli Lilly—are …
GLP-1 Drugs
Novo Nordisk or Eli Lilly? The GLP-1 Battle That’s Reshaping Healthcare
The global market for GLP-1 medicines continues to attract significant attention from patients, healthcare professionals, investors, and pharmaceutical companies. Novo Nordisk …
Eli Lilly Expands U.S. Manufacturing in 2026: What It Means for GLP-1 Drugs, Pharma Jobs, and Healthcare Innovation
The demand for GLP-1 medicines used in diabetes care and, where approved, chronic weight management has grown rapidly in recent years. …
Generic GLP-1 Drugs Could Change the Weight-Loss Market—FDA Begins Review
The U.S. market for GLP-1 medicines continues to expand rapidly as demand for obesity and diabetes treatments grows. In another important …
Dr. Reddy’s Semaglutide Supply Delay: What It Means for the Global GLP-1 Market in 2026
The global race to expand access to GLP-1 medicines has reached another important milestone after Dr. Reddy’s Laboratories announced a temporary …